Legend Biotech Corporation
Price Action
Technical Summary
CONSOLIDATINGLegend Biotech Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings growth of 45% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $31.95 | -12.59% | BELOW |
| 50 SMA | $27.74 | +0.69% | ABOVE |
| 100 SMA | $22.95 | +21.67% | ABOVE |
| 150 SMA | $23.31 | +19.83% | ABOVE |
| 200 SMA | $25.69 | +8.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LEGN in an uptrend right now?
LEGN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is LEGN overbought or oversold?
LEGN's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is LEGN outperforming the market?
LEGN has a Relative Strength (RS) Rating of 82 out of 99. Yes, LEGN is a market leader, outperforming 82% of all stocks over the past 12 months.
Where is LEGN in its 52-week range?
LEGN is trading at $27.93, which is 62% of its 52-week high ($45.30) and 40% above its 52-week low ($16.24).
How volatile is LEGN?
LEGN has a Beta of 0.59 and 52-week volatility of 70%. It's less volatile than the S&P 500 - generally more stable.